NIVF Relative Valuation
NIVF's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NIVF is overvalued; if below, it's undervalued.
Historical Valuation
NewGenIvf Group Ltd (NIVF) is now in the Fair zone, suggesting that its current forward PS ratio of 0.02 is considered Fairly compared with the five-year average of 0.06. The fair price of NewGenIvf Group Ltd (NIVF) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：0.61
Fair
0.25
PE
1Y
3Y
5Y
0.00
EV/EBITDA
NewGenIvf Group Ltd. (NIVF) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
0.15
EV/EBIT
NewGenIvf Group Ltd. (NIVF) has a current EV/EBIT of 0.15. The 5-year average EV/EBIT is 0.03. The thresholds are as follows: Strongly Undervalued below -0.20, Undervalued between -0.20 and -0.09, Fairly Valued between 0.15 and -0.09, Overvalued between 0.15 and 0.27, and Strongly Overvalued above 0.27. The current Forward EV/EBIT of 0.15 falls within the Historic Trend Line -Fairly Valued range.
0.02
PS
NewGenIvf Group Ltd. (NIVF) has a current PS of 0.02. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below -0.03, Undervalued between -0.03 and -0.01, Fairly Valued between 0.02 and -0.01, Overvalued between 0.02 and 0.03, and Strongly Overvalued above 0.03. The current Forward PS of 0.02 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
NewGenIvf Group Ltd. (NIVF) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.
0.00
P/FCF
NewGenIvf Group Ltd. (NIVF) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
NewGenIvf Group Ltd (NIVF) has a current Price-to-Book (P/B) ratio of 0.01. Compared to its 3-year average P/B ratio of 2.96 , the current P/B ratio is approximately -99.67% higher. Relative to its 5-year average P/B ratio of 2.52, the current P/B ratio is about -99.61% higher. NewGenIvf Group Ltd (NIVF) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -135.54%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -112.99% , the current FCF yield is about -100.00% lower.
0.01
P/B
Median3y
2.96
Median5y
2.52
0.00
FCF Yield
Median3y
-135.54
Median5y
-112.99
Competitors Valuation Multiple
The average P/S ratio for NIVF's competitors is 10.60, providing a benchmark for relative valuation. NewGenIvf Group Ltd Corp (NIVF) exhibits a P/S ratio of 0.02, which is -99.83% above the industry average. Given its robust revenue growth of -12.94%, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of NIVF decreased by 99.92% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 0.00 to 0.01.
The secondary factor is the Revenue Growth, contributed -12.94%to the performance.
Overall, the performance of NIVF in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
Frequently Asked Questions
Is NewGenIvf Group Ltd (NIVF) currently overvalued or undervalued?
NewGenIvf Group Ltd (NIVF) is now in the Fair zone, suggesting that its current forward PS ratio of 0.02 is considered Fairly compared with the five-year average of 0.06. The fair price of NewGenIvf Group Ltd (NIVF) is between to according to relative valuation methord.
What is NewGenIvf Group Ltd (NIVF) fair value?
NIVF's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of NewGenIvf Group Ltd (NIVF) is between to according to relative valuation methord.
How does NIVF's valuation metrics compare to the industry average?
The average P/S ratio for NIVF's competitors is 10.60, providing a benchmark for relative valuation. NewGenIvf Group Ltd Corp (NIVF) exhibits a P/S ratio of 0.02, which is -99.83% above the industry average. Given its robust revenue growth of -12.94%, this premium appears unsustainable.
What is the current P/B ratio for NewGenIvf Group Ltd (NIVF) as of Jan 08 2026?
As of Jan 08 2026, NewGenIvf Group Ltd (NIVF) has a P/B ratio of 0.01. This indicates that the market values NIVF at 0.01 times its book value.
What is the current FCF Yield for NewGenIvf Group Ltd (NIVF) as of Jan 08 2026?
As of Jan 08 2026, NewGenIvf Group Ltd (NIVF) has a FCF Yield of 0.00%. This means that for every dollar of NewGenIvf Group Ltd’s market capitalization, the company generates 0.00 cents in free cash flow.
What is the current Forward P/E ratio for NewGenIvf Group Ltd (NIVF) as of Jan 08 2026?
As of Jan 08 2026, NewGenIvf Group Ltd (NIVF) has a Forward P/E ratio of 0.25. This means the market is willing to pay $0.25 for every dollar of NewGenIvf Group Ltd’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for NewGenIvf Group Ltd (NIVF) as of Jan 08 2026?
As of Jan 08 2026, NewGenIvf Group Ltd (NIVF) has a Forward P/S ratio of 0.02. This means the market is valuing NIVF at $0.02 for every dollar of expected revenue over the next 12 months.